



**HAL**  
open science

## **Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren**

Tuija Tapaninen, Pertti J. Neuvonen, Mikko Niemi

► **To cite this version:**

Tuija Tapaninen, Pertti J. Neuvonen, Mikko Niemi. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. *European Journal of Clinical Pharmacology*, 2010, 66 (5), pp.497-502. <10.1007/s00228-010-0796-3>. <hal-00568944>

**HAL Id: hal-00568944**

**<https://hal.science/hal-00568944v1>**

Submitted on 24 Feb 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization



**Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren**

Journal:	<i>European Journal of Clinical Pharmacology</i>
Manuscript ID:	EJCP-2009-0369.R1
Type of submission:	Original
Date Submitted by the Author:	26-Jan-2010
Complete List of Authors:	Tapaninen, Tuija; University of Helsinki, Department of Clinical Pharmacology Neuvonen, Pertti; University of Helsinki, Department of Clinical Pharmacology Niemi, Mikko; University of Helsinki and Helsinki University Central Hospital, Department of Clinical Pharmacology

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren

Tuija Tapaninen, Pertti J. Neuvonen and Mikko Niemi

Department of Clinical Pharmacology, University of Helsinki and Helsinki University

Central Hospital, Helsinki, Finland

## Correspondence and requests for reprints:

Mikko Niemi, MD

Department of Clinical Pharmacology,

Helsinki University Central Hospital

PO Box 705, FI-00029 HUS, Finland

Fax: +358-9-471 74039

E-mail: [mikko.niemi@helsinki.fi](mailto:mikko.niemi@helsinki.fi)

**Word count:** 2099 words (excluding the title page, summary, references, tables, and  
figures)

A revised manuscript (EJCP-2009-0369) for *European Journal of Clinical  
Pharmacology*, including 21 pages, 2 tables, and 3 figures (January 2010).

**ABSTRACT*****Purpose***

This study aimed to investigate the effect of rifampicin, an inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of aliskiren, a renin inhibitor used in the treatment of hypertension.

***Methods***

In a randomized crossover study, twelve healthy volunteers took 600 mg rifampicin or placebo once daily for five days. On day six, they ingested a single 150 mg dose of aliskiren. Plasma aliskiren concentrations were measured up to 72 h and urine concentrations up to 12 h, pharmacodynamic variables were measured up to 24 h.

***Results***

Rifampicin reduced the peak plasma aliskiren concentration ( $C_{max}$ ) by 39% (95% confidence interval 0.41, 0.90;  $P=0.017$ ) and the area under the plasma aliskiren concentration-time curve ( $AUC_{0-\infty}$ ) by 56% (95% confidence interval 0.35, 0.56;  $P<0.001$ ). Rifampicin had no significant effect on aliskiren elimination half-life ( $t_{1/2}$ ) or its renal clearance ( $Cl_{renal}$ ). Plasma renin activity 24 h after aliskiren intake was 61% higher during the rifampicin phase than during the placebo phase ( $P=0.008$ ).

***Conclusions***

Rifampicin considerably reduces the plasma concentrations and the renin-inhibiting effect of aliskiren by decreasing its oral bioavailability.

**KEYWORDS** Pharmacokinetics, Drug interaction, Aliskiren, Rifampicin, Multidrug resistance transporter 1 P-glycoprotein

## INTRODUCTION

Aliskiren is a renin inhibitor, which belongs to a class of antihypertensive drugs acting on the renin-angiotensin-aldosterone system [1-3]. It has a low oral bioavailability of about 2-3%, probably mainly because of poor absorption [3-5]. The peak plasma aliskiren concentration ( $C_{max}$ ) is reached within 1 to 3 h. Aliskiren is eliminated primarily in the unchanged form by biliary excretion into the feces and, to a lesser extent, by renal excretion of unchanged aliskiren (about 0.4% of oral dose) and by oxidative biotransformation (about 1.4% of oral dose), mainly via CYP3A4 [5]. The elimination half-life ( $t_{1/2}$ ) of aliskiren is about 30-40 h.

Aliskiren is a substrate of the multidrug resistance transporter 1 (MDR1) P-glycoprotein, but not of breast cancer resistance protein or multidrug resistance-associated protein 2 [6]. P-glycoprotein efflux transporter is expressed on the apical membrane of small intestinal enterocytes, hepatocytes, and proximal tubule cells and can reduce the intestinal absorption and enhance the elimination of its substrates [7]. In addition, P-glycoprotein is expressed at blood-tissue barriers, such as blood-brain barrier, protecting tissues from potentially toxic xenobiotics [7]. The hepatic uptake of aliskiren is thought to be mediated by organic anion transporting polypeptide 2B1 (OATP2B1) [6]. Ketoconazole (an inhibitor of both CYP3A4 and P-glycoprotein [8-11]) and cyclosporine (a potent inhibitor of CYP3A4, P-glycoprotein, and OATP2B1 [12-14]) have raised the area under the plasma aliskiren concentration-time curve (AUC) 1.8-fold and 5-fold, respectively [6, 15].

1  
2  
3  
4 Rifampicin is an inducer of several drug-metabolizing enzymes (including CYP3A4)  
5  
6 and of some drug transporters (such as P-glycoprotein), and can markedly reduce the  
7  
8 plasma concentrations and efficacy of several CYP3A4 and P-glycoprotein substrates  
9  
10 [16-22]. However, there are no published studies on the interactions of aliskiren with  
11  
12 inducers of CYP3A4 and P-glycoprotein. Our aim was to study the possible effects of  
13  
14 rifampicin on the pharmacokinetics and pharmacodynamics of aliskiren. The hypothesis  
15  
16 was that rifampicin may reduce the plasma concentrations and the renin-inhibiting  
17  
18 effect of aliskiren.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## METHODS

### Subjects

Twelve healthy white Finnish volunteers (7 women, 5 men) participated in the study after giving written informed consent. Their mean  $\pm$  SD age was  $21 \pm 2$  years (range, 20-25 years), mean height  $174 \pm 10$  cm (range, 156-187 cm), and mean weight  $66 \pm 11$  kg (range, 50-89 kg). Participants were ascertained to be healthy by medical history, physical examination, and routine laboratory tests. Subjects with a systolic blood pressure less than 110 mm Hg were not included in the study. None of the participants was on any continuous medication, including oral contraceptives, and none was a tobacco smoker.

### Study design

The study protocol was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District, and the National Agency for Medicines in Finland. In a randomized two-phase crossover study with a wash-out period of four weeks, the volunteers took 600 mg rifampicin (Rimapen; Orion Pharma, Espoo, Finland) or placebo once daily at 20.00 h for five days. On day six, after an overnight fast, a single oral dose of 150 mg aliskiren (Rasilez; Novartis, Horsham, Great Britain) was administered with 150 ml of water at 08.00 h. A standardized warm meal was served 4 h after the administration of aliskiren, and a standardized light meal after 7 h and 10 h. The participants were under direct medical supervision for 12 h after aliskiren ingestion. Fluids for intravenous infusion were available for immediate use in case of hypotension, but were not needed. Use of other drugs was prohibited for one week before and after,

1  
2  
3  
4 and use of grapefruit products and alcohol for five days before and three days after  
5  
6  
7 aliskiren administration.  
8  
9

### 10 11 **Blood sampling and pharmacodynamic measurements** 12

13  
14 On the days of the administration of aliskiren, a forearm vein of each subject was  
15  
16 cannulated with a plastic cannula and kept patent with an obturator. Timed blood  
17  
18 samples for drug concentration measurements (5 or 10 ml each) were drawn into tubes  
19  
20 containing ethylenediaminetetraacetic acid (EDTA) prior to and 0.5, 1, 2, 3, 4, 5, 7, 9,  
21  
22 12, 24, 34, 48, and 72 h after aliskiren administration. Blood samples for the  
23  
24 determination of plasma renin activity (5 ml each) were drawn before the administration  
25  
26 of aliskiren and 4 h and 24 h thereafter into chilled EDTA tubes, which were placed on  
27  
28 ice immediately after sampling. Plasma was separated within 30 min. Urine was  
29  
30 collected up to 12 h after aliskiren ingestion. Urine aliquots and plasma were stored at -  
31  
32 70°C until analysis. Plasma renin activity was measured using a commercially available  
33  
34 radioimmunoassay method (RENCTK; DiaSorin, Saluggia, Italy). Systolic and diastolic  
35  
36 blood pressures, and heart rate were measured twice (mean value was used in the  
37  
38 calculations) from the forearm with an automatic oscillometric blood pressure monitor  
39  
40 (Omron M5-I; Omron Healthcare Europe BV, Hoofddorp, The Netherlands), with the  
41  
42 subject in a sitting position, prior to and 2, 4, 7, 9, 12, and 24 h after the administration  
43  
44 of aliskiren.  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Determination of aliskiren concentrations** 55

56 Plasma and urine concentrations of aliskiren were quantified using an Applied  
57  
58 Biosystems SCIEX API 2000 Q Trap liquid chromatography-tandem mass spectrometry  
59  
60



(LC/MS/MS) system (Sciex Division of MDS Inc, Toronto, Ontario, Canada) [5].

Acebutolol served as an internal standard. The limit of quantification of plasma aliskiren was 0.25 ng/ml, and the intra-day coefficient of variation (CV) was 1.2% at 2 ng/ml, 1.0% at 20 ng/ml, and 1.2% at 200 ng/ml ( $n=6$ ). The calibration curve for plasma aliskiren was linear over the range 0.25-500 ng/ml ( $r>0.999$ , weighting  $1/x$ ). The limit of quantification of aliskiren in urine was 9 ng/ml, and the intra-day CV was 4.8% at 9 ng/ml, 4.5% at 120 ng/ml, and 3.4% at 1200 ng/ml ( $n=6$ ). The calibration curve for urine aliskiren was linear over the range 9-1800 ng/ml ( $r>0.999$ , weighting  $1/x$ ).

### Pharmacokinetics

The pharmacokinetics of aliskiren were characterized by  $C_{\max}$ , time to  $C_{\max}$  ( $t_{\max}$ ),  $t_{1/2}$ ,  $AUC_{0-72}$ ,  $AUC_{0-\infty}$ , the amount of aliskiren excreted into urine from 0 to 12 h ( $A_e$ ), and the renal clearance ( $Cl_{\text{renal}}$ ). Pharmacokinetic parameters were calculated with non-compartmental methods using MK-Model, version 5.0 (Biosoft, Cambridge, United Kingdom). The terminal log-linear part of each concentration-time curve was identified visually. The elimination rate constant ( $k_e$ ) was determined by linear regression analysis of the log-linear part of the plasma drug concentration-time curve. The  $t_{1/2}$  was calculated by the equation  $t_{1/2} = \ln 2/k_e$ . The AUC values were calculated by a combination of the linear and log-linear trapezoidal rules with extrapolation to infinity, when appropriate, by division of the last measured concentration by  $k_e$ . The  $Cl_{\text{renal}}$  of aliskiren was calculated by the equation  $Cl_{\text{renal}} = A_e/AUC_{0-12}$ .

### Pharmacodynamics

1  
2  
3  
4 The pharmacodynamics of aliskiren were characterized by plasma renin activity at 4 h  
5 and 24 h after aliskiren intake, as well as average systolic and diastolic blood pressures,  
6 and heart rate. Average values of systolic and diastolic blood pressures and heart rate  
7 were calculated by dividing the area under the effect-time curve from 0 to 24 h by 24 h.  
8  
9  
10  
11  
12  
13

### 16 **Statistical analysis**

17  
18 The results are expressed as geometric means (95% confidence interval), unless  
19 otherwise indicated. The  $C_{\max}$ , AUC, Ae, and  $Cl_{\text{renal}}$  data were logarithmically  
20 transformed before statistical analysis. Statistical comparisons of the pharmacokinetic  
21 (other than  $t_{\max}$ ) and pharmacodynamic variables during the placebo and rifampicin  
22 phases were carried out using repeated-measures analysis of variance with treatment  
23 phase as a within-subjects factor and treatment sequence as a between-subjects factor.  
24 The  $t_{\max}$  data were compared using the Wilcoxon signed rank test. The frequencies of  
25 individuals with a double-peak in aliskiren plasma concentration curve were compared  
26 between the phases using the McNemar test. Possible correlations between the  
27 pharmacokinetic variables of aliskiren and subject body weight were analyzed with the  
28 Pearson correlation coefficient. The data were analyzed using the statistical program  
29 SPSS 16.0 for Windows (SPSS, Chicago, IL, USA). Differences were considered  
30 statistically significant when  $P$  was  $<0.05$ . The number of subjects was estimated to be  
31 sufficient to detect a 40% difference in the  $AUC_{0-\infty}$  of aliskiren between the placebo and  
32 rifampicin phases, with a power of 80% ( $\alpha$ -level 5%) [4].  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## RESULTS

### Effect of rifampicin on aliskiren pharmacokinetics

Rifampicin markedly reduced the plasma concentrations of aliskiren (Fig. 1, Table 1). The  $C_{\max}$  of aliskiren was reduced by 39% ( $P=0.017$ ) and its  $AUC_{0-\infty}$  by 56% ( $P<0.001$ ) by rifampicin. The  $A_e$  was decreased by 48% by rifampicin ( $P=0.001$ ). Rifampicin had no significant effect on the  $t_{\max}$ ,  $t_{1/2}$ , or  $Cl_{\text{renal}}$  of aliskiren. The extent of the interaction showed marked interindividual variability: decrease in aliskiren  $AUC_{0-\infty}$  ranged from 20% to 76% and the effect of rifampicin on the aliskiren  $C_{\max}$  ranged from a 78% decrease to a 9% increase (Fig. 2). Plasma aliskiren concentration showed a double-peak in 11 out of 12 subjects during the placebo phase and 6 out of 12 subjects during the rifampicin phase ( $P=0.063$ ). None of the pharmacokinetic variables of aliskiren correlated with subject body weight, during either the placebo or rifampicin phase ( $|r|<0.38$ ,  $P>0.23$ ).

### Effect of rifampicin on aliskiren pharmacodynamics

Plasma renin activity 24 h after aliskiren intake was 61% higher during the rifampicin phase than during the placebo phase ( $P=0.008$ ) (Fig. 3, Table 2). No significant difference existed in the systolic or diastolic blood pressure, or the heart rate between the rifampicin and placebo phases.

## DISCUSSION

This study demonstrates that rifampicin markedly reduces the plasma concentrations of aliskiren. The  $C_{\max}$  and  $AUC_{0-\infty}$  of aliskiren were reduced by 39% and 56%, respectively. Marked interindividual variability was evident in the extent of the interaction. Plasma renin activity 24 h after aliskiren intake was 61% higher during the rifampicin phase than during the placebo phase. The interaction between rifampicin and aliskiren may result in a need to adjust aliskiren dose.

Aliskiren, a drug with a low oral bioavailability, is a substrate of P-glycoprotein efflux transporter and is slightly metabolized by CYP3A4 [3, 5, 6]. In the present study, rifampicin reduced the  $C_{\max}$  and  $AUC_{0-\infty}$  of aliskiren without affecting the  $t_{1/2}$  or the  $Cl_{\text{renal}}$ , indicating that rifampicin increased mainly the first-pass elimination of aliskiren with no or minimal effect on its systemic clearance. Rifampicin has a strong inducing effect on intestinal and hepatic CYP3A4 with a smaller, though significant, effect on P-glycoprotein [16-22]. It is noteworthy that intestinal CYP3A4 and P-glycoprotein act synergistically to reduce the oral bioavailability of their joint substrates [23].

Because aliskiren has a low hepatic extraction ratio (0.10) [24], induction of its hepatic elimination unlikely explains this interaction observed during the first-pass phase.

Moreover, significant change in the hepatic extraction of such a drug with a low hepatic extraction should result in a shortened elimination  $t_{1/2}$ . In addition, plasma aliskiren concentration data showed double-peaks characteristic of entero-hepatic circulation, particularly during the placebo phase. This phenomenon appeared to be diminished

1  
2  
3  
4 during the rifampicin phase, consistent with reduced intestinal reabsorption of aliskiren  
5  
6 due to induction of intestinal P-glycoprotein and CYP3A4. Taken together, the  
7  
8 interaction between rifampicin and aliskiren is most likely caused by induction of P-  
9  
10 glycoprotein-mediated efflux and CYP3A4-catalyzed biotransformation of aliskiren in  
11  
12 the gut wall [16-22].  
13  
14  
15  
16  
17

18  
19 In this study, the renin-inhibiting effect of aliskiren was attenuated during the rifampicin  
20  
21 phase. However, no differences in hemodynamic effects were observed between the  
22  
23 rifampicin and placebo phases after a single dose of aliskiren in healthy volunteers. This  
24  
25 can be explained by the delayed start of the blood pressure decreasing effect of  
26  
27 aliskiren, which gradually reaches its maximum after four weeks treatment [15, 25].  
28  
29 Moreover, the pharmacodynamic response to aliskiren in patients with hypertension  
30  
31 may be distinct from normotensive healthy individuals [3, 15]. On the other hand, the  
32  
33 pharmacokinetics of aliskiren is similar in patients with hypertension and healthy  
34  
35 individuals [3, 15]. According to pharmacokinetic theory, the dose-interval AUC at  
36  
37 steady state is equal to the  $AUC_{0-\infty}$  after a single dose [26]. However, the  
38  
39 pharmacokinetics of aliskiren is slightly non-linear [3], interfering with the direct  
40  
41 extrapolation of the present results to steady-state. Because aliskiren shows a dose-  
42  
43 response relationship in the range 150-300 mg, but no clear effect on blood pressure  
44  
45 with lower doses [15, 25], it is possible that rifampicin reduces the efficacy of aliskiren  
46  
47 in patients with hypertension. Similarly to rifampicin, a high-fat meal has reduced the  
48  
49 AUC of aliskiren by about 70% [3]. To minimize variability due to the food effect,  
50  
51 aliskiren is recommended to be taken once daily with a light meal or in a routine pattern  
52  
53 with regard to meals [15, 27].  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 In conclusion, rifampicin considerably reduces the plasma concentrations of aliskiren.

8  
9 Clinicians should be aware of the possibility that rifampicin may reduce the  
10  
11 antihypertensive efficacy of aliskiren.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

**ACKNOWLEDGEMENTS**

We thank Kaisa Kurkinen for the drug concentration measurements, and Mikko Neuvonen, Eija Mäkinen-Pulli, Lisbet Partanen and Jouko Laitila for skilled assistance. This study was supported by grants from the Helsinki University Central Hospital Research Fund (Helsinki, Finland) and the Sigrid Jusélius Foundation (Helsinki, Finland).

**COMPETING INTEREST**

None to declare.

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1 Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüger H, Göschke R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. *Biochem Biophys Res Commun* 308 (4): 698-705
- 2 Skeggs LT, Jr., Kahn JR, Lentz K, Shumway NP (1957) The preparation, purification, and amino acid sequence of a polypeptide renin substrate. *J Exp Med* 106 (3): 439-453
- 3 Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP (2008) Clinical pharmacokinetics and pharmacodynamics of aliskiren. *Clin Pharmacokinet* 47 (8): 515-531
- 4 Vaidyanathan S, Jermay J, Yeh C, Bizot MN, Camisasca R (2006) Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. *Br J Clin Pharmacol* 62 (6): 690-698
- 5 Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S (2007) Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. *Drug Metab Dispos* 35 (8): 1418-1428



1  
2  
3  
4  
5 6 Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot  
6  
7 MN, Dieterich HA, Howard D, Dole WP (2008) Pharmacokinetics of the oral direct  
8  
9 renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in  
10  
11 healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. *J Clin*  
12  
13 *Pharmacol* 48 (11): 1323-1338  
14  
15

16  
17  
18 7 Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers.  
19  
20 *Trends Pharmacol Sci* 25 (8): 423-429  
21  
22

23  
24  
25 8 Jurima-Romet M, Crawford K, Cyr T, Inaba T (1994) Terfenadine  
26  
27 metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole  
28  
29 antifungals. *Drug Metab Dispos* 22 (6): 849-857  
30  
31

32  
33  
34 9 Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be  
35  
36 avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.  
37  
38 *Clin Pharmacol Ther* 55 (5): 481-485  
39  
40

41  
42  
43 10 Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW (2002)  
44  
45 Interaction of common azole antifungals with P glycoprotein. *Antimicrob Agents*  
46  
47 *Chemother* 46 (1): 160-165  
48  
49

50  
51  
52 11 Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human  
53  
54 MDR1 (P-glycoprotein): recent advances and clinical relevance. *Clin Pharmacol Ther*  
55  
56 *75* (1): 13-33  
57  
58  
59  
60

- 1  
2  
3  
4  
5 12 Rao US, Scarborough GA (1994) Direct demonstration of high affinity  
6 interactions of immunosuppressant drugs with the drug binding site of the human P-  
7 glycoprotein. *Mol Pharmacol* 45 (4): 773-776  
8  
9  
10  
11  
12  
13  
14 13 Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT  
15 (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. *Clin*  
16 *Pharmacol Ther* 78 (4): 388-399  
17  
18  
19  
20  
21  
22  
23 14 Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y,  
24 Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function,  
25 expression, and pharmacogenetics. *Gastroenterology* 130 (6): 1793-1806  
26  
27  
28  
29  
30  
31  
32 15 European Public Assessment Report for Rasilez. Available from  
33 URL:<http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm>.  
34  
35  
36 Accessed Nov 17, 2009  
37  
38  
39  
40  
41 16 Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P  
42 (1989) Metabolism of cyclosporin A. IV. Purification and identification of the  
43 rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a  
44 product of P450III A gene subfamily. *Drug Metab Dispos* 17 (2): 197-207  
45  
46  
47  
48  
49  
50  
51  
52 17 Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992)  
53 Identification of rifampin-inducible P450III A4 (CYP3A4) in human small bowel  
54 enterocytes. *J Clin Invest* 90 (5): 1871-1878  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 18 Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of  
5  
6 P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in  
7  
8 human colon carcinoma cells. *Mol Pharmacol* 49 (2): 311-318  
9

10  
11  
12  
13 19 Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically  
14  
15 reduces plasma concentrations and effects of oral midazolam. *Clin Pharmacol Ther* 59  
16  
17 (1): 7-13  
18  
19

20  
21  
22 20 Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ (1998) The area  
23  
24 under the plasma concentration-time curve for oral midazolam is 400-fold larger during  
25  
26 treatment with itraconazole than with rifampicin. *Eur J Clin Pharmacol* 54 (1): 53-58  
27  
28  
29

30  
31 21 Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O,  
32  
33 Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of  
34  
35 digoxin and rifampin. *J Clin Invest* 104 (2): 147-153  
36  
37  
38

39  
40 22 Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT (2003)  
41  
42 Pharmacokinetic interactions with rifampicin : clinical relevance. *Clin Pharmacokinet*  
43  
44 42 (9): 819-850  
45  
46  
47

48  
49 23 Kivistö KT, Niemi M, Fromm MF (2004) Functional interaction of  
50  
51 intestinal CYP3A4 and P-glycoprotein. *Fundam Clin Pharmacol* 18 (6): 621-626  
52  
53  
54

55  
56 24 Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition  
57  
58 with aliskiren: where are we now, and where are we going? *J Hypertens* 24 (2): 243-256  
59  
60

1  
2  
3  
4 25 Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL (2007)  
5  
6 Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-  
7  
8 hour blood pressure control in patients with hypertension. *J Am Coll Cardiol* 49 (11):  
9  
10 1157-63  
11  
12

13  
14  
15  
16 26 Rowland M, Tozer TN (1995) *Clinical pharmacokinetics: Concepts and*  
17  
18 *applications*, 3rd edn. Williams & Wilkins, Baltimore  
19  
20

21  
22 27 Tekturna Prescribing Information. Available from  
23  
24 URL:<http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf>. Accessed Nov  
25  
26  
27 17, 2009  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1** Pharmacokinetic variables of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily

Variable	Placebo phase (control)	Rifampicin phase	Geometric mean ratio/ mean difference (95% CI)	<i>P</i> value
$C_{\max}$ (ng/ml)	137 (83, 226)	83 (59, 118)	0.61 (0.41, 0.90)	0.017
$t_{\max}$ (h)	1 (0.5-5)	0.5 (0.5-5)		0.254
$t_{1/2}$ (h)	28.4 ± 8.5	24.4 ± 7.4	-4.0 (-9.6, 1.6)*	0.143
AUC <sub>0-72</sub> (ng·h/ml)	537 (349, 825)	244 (182, 325)	0.45 (0.36, 0.57)	<0.001
AUC <sub>0-∞</sub> (ng·h/ml)	581 (376, 898)	258 (191, 349)	0.44 (0.35, 0.56)	<0.001
Ae (mg)	0.576 (0.403, 0.822)	0.299 (0.227, 0.394)	0.52 (0.38, 0.72)	0.001
Cl <sub>renal</sub> (l/h)	1.52 (1.21, 1.91)	1.63 (1.38, 1.93)	1.07 (0.91, 1.26)	0.347

Data are given as geometric mean (95% CI),  $t_{\max}$  data as median (range), and  $t_{1/2}$  data as mean ± SD.

CI, Confidence interval;  $C_{\max}$ , peak plasma concentration;  $t_{\max}$ , time to  $C_{\max}$ ;  $t_{1/2}$ , elimination half-life; AUC<sub>0-72</sub>, area under the plasma concentration-time curve from 0 to 72 h; AUC<sub>0-∞</sub>, area under the plasma concentration-time curve from time 0 to infinity; Ae, amount excreted into urine within 12 h; Cl<sub>renal</sub>, renal clearance.

\*Mean difference (95% CI).

**Table 2** Pharmacodynamic variables of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily

Variable	Placebo phase (control)	Rifampicin phase	Mean difference (95% CI)	<i>P</i> value
Plasma renin activity (ng/ml/h)				
Baseline	2.21 ± 1.95	2.20 ± 1.40	-0.01 (-1.04, 1.01)	0.980
At 4 h	0.01 ± 0.04	0.19 ± 0.39	0.18 (-0.09, 0.45)	0.166
At 24 h	1.27 ± 1.20	2.04 ± 1.11	0.77 (0.25, 1.29)	0.008
Systolic blood pressure (mm Hg)				
Baseline	124 ± 15	127 ± 15	4 (-1, 8)	0.078
Average <sub>0-24h</sub>	126 ± 13	126 ± 16	0 (-4, 4)	0.847
Average <sub>0-24h</sub> /Baseline	1.02 ± 0.06	0.99 ± 0.03	-0.03 (-0.07, 0.01)	0.093
Diastolic blood pressure (mm Hg)				
Baseline	77 ± 11	76 ± 9	0 (-5, 5)	0.926
Average <sub>0-24h</sub>	74 ± 10	73 ± 8	-1 (-6, 3)	0.482
Average <sub>0-24h</sub> /Baseline	0.97 ± 0.06	0.95 ± 0.06	-0.02 (-0.07, 0.04)	0.544
Heart rate (1/min)				
Baseline	63 ± 13	64 ± 7	1 (-5, 7)	0.729
Average <sub>0-24h</sub>	70 ± 12	69 ± 9	0 (-5, 5)	0.888
Average <sub>0-24h</sub> /Baseline	1.11 ± 0.09	1.08 ± 0.07	-0.03 (-0.08, 0.02)	0.233

Data are given as mean ± SD.


CI, Confidence interval; Baseline, before the administration of aliskiren.

**FIGURE LEGENDS**

**Fig. 1** Geometric mean (95% confidence interval) plasma concentrations of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily. Inset depicts the same data on a semi-logarithmic scale

**Fig. 2** Box-and-whisker plots of the  $C_{\max}$ , AUC and  $t_{1/2}$  values of aliskiren. A single 150 mg oral dose of aliskiren was given to twelve healthy volunteers following a 5-day treatment with 600 mg rifampicin or placebo once daily. The horizontal lines inside the boxes represent the median, the box edges show the lower and upper quartiles, and the whiskers show the 5th and 95th percentiles. Individual data points are given as open (placebo phase) and solid (rifampicin phase) circles


**Fig. 3** Box-and-whisker plots of plasma renin activity in twelve healthy volunteers 0, 4, and 24 after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily. The horizontal lines inside the boxes represent the median, the box edges show the lower and upper quartiles, and the whiskers show the 5th and 95th percentiles. Individual data points are given as open (placebo phase) and solid (rifampicin phase) circles




1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren

Tuija Tapaninen, Pertti J. Neuvonen and Mikko Niemi

Department of Clinical Pharmacology, University of Helsinki and Helsinki University

Central Hospital, Helsinki, Finland

### Correspondence and requests for reprints:

Mikko Niemi, MD

Department of Clinical Pharmacology,

Helsinki University Central Hospital

PO Box 705, FI-00029 HUS, Finland

Fax: +358-9-471 74039

E-mail: [mikko.niemi@helsinki.fi](mailto:mikko.niemi@helsinki.fi)

Word count: ~~2099~~ words (excluding the title page, summary, references, tables, and  
figures)

Deleted: 074

A ~~revised~~ manuscript ([EJCP-2009-0369](#)) for *European Journal of Clinical  
Pharmacology*, including ~~21~~ pages, 2 tables, and 3 figures ([January 2010](#)).

Deleted: 3

Deleted: November

Deleted: 2009

Deleted: November

Deleted: 09

**ABSTRACT****Purpose**

This study aimed to investigate the effect of rifampicin, an inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics and pharmacodynamics of aliskiren, a renin inhibitor used in the treatment of hypertension.

Deleted: the

**Methods**

In a randomized crossover study, twelve healthy volunteers took 600 mg rifampicin or placebo once daily for five days. On day six, they ingested a single 150 mg dose of aliskiren. Plasma aliskiren concentrations were measured up to 72 h and urine concentrations up to 12 h, pharmacodynamic variables were measured up to 24 h.

**Results**

Rifampicin reduced the peak plasma aliskiren concentration ( $C_{max}$ ) by 39% (95% confidence interval 0.41, 0.90;  $P=0.017$ ) and the area under the plasma aliskiren concentration-time curve ( $AUC_{0-\infty}$ ) by 56% (95% confidence interval 0.35, 0.56;  $P<0.001$ ). Rifampicin had no significant effect on aliskiren elimination half-life ( $t_{1/2}$ ) or its renal clearance ( $Cl_{renal}$ ). Plasma renin activity 24 h after aliskiren intake was 61% higher during the rifampicin phase than during the placebo phase ( $P=0.008$ ).

Deleted: mean

Deleted: 47

Deleted: geometric mean ratio 0.61,

Deleted:

Deleted:

Deleted: mean

Deleted: 60

Deleted: geometric mean ratio 0.44,

Deleted:

Deleted:

Deleted:

Deleted:

**Conclusions**

Rifampicin considerably reduces the plasma concentrations and the renin-inhibiting effect of aliskiren by decreasing its oral bioavailability.

Deleted: , probably by inducing the P-glycoprotein-mediated transport and CYP3A4-catalyzed biotransformation of aliskiren in the small intestine

**KEYWORDS** Pharmacokinetics, Drug interaction, Aliskiren, Rifampicin, Multidrug resistance transporter 1 P-glycoprotein

Deleted: CYP3A4,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

Aliskiren is a renin inhibitor, which belongs to a class of antihypertensive drugs acting on the renin-angiotensin-aldosterone system [1-3]. It has a low oral bioavailability of about 2-3%, probably mainly because of poor absorption [3-5]. The peak plasma aliskiren concentration ( $C_{max}$ ) is reached within 1 to 3 h. Aliskiren is eliminated primarily in the unchanged form by biliary excretion into the feces and, to a lesser extent, by renal excretion of unchanged aliskiren (about 0.4% of oral dose) and by oxidative biotransformation (about 1.4% of oral dose), mainly via CYP3A4 [5]. The elimination half-life ( $t_{1/2}$ ) of aliskiren is about 30-40 h.

Aliskiren is a substrate of the multidrug resistance transporter 1 (MDR1) P-glycoprotein, but not of breast cancer resistance protein or multidrug resistance-associated protein 2 [6]. P-glycoprotein efflux transporter is expressed on the apical membrane of small intestinal enterocytes, hepatocytes, and proximal tubule cells and can reduce the intestinal absorption and enhance the elimination of its substrates [7]. In addition, P-glycoprotein is expressed at blood-tissue barriers, such as blood-brain barrier, protecting tissues from potentially toxic xenobiotics [7]. The hepatic uptake of aliskiren is thought to be mediated by organic anion transporting polypeptide 2B1 (OATP2B1) [6]. Ketoconazole (an inhibitor of both CYP3A4 and P-glycoprotein [8-11]) and cyclosporine (a potent inhibitor of CYP3A4, P-glycoprotein, and OATP2B1 [12-14]) have raised the area under the plasma aliskiren concentration-time curve (AUC) 1.8-fold and 5-fold, respectively [6, 15].

Deleted: the

Deleted: the

Deleted: November

Deleted: 09

1  
2  
3 Rifampicin is an inducer of several drug-metabolizing enzymes (including CYP3A4)

4 and of some drug transporters (such as P-glycoprotein), and can markedly reduce the

Deleted: the

5  
6 plasma concentrations and efficacy of several CYP3A4 and P-glycoprotein substrates

7  
8 [16-22]. However, there are no published studies on the interactions of aliskiren with

9  
10 inducers of CYP3A4 and P-glycoprotein. Our aim was to study the possible effects of

Deleted: the

Deleted: Therefore, we found it important

11  
12 rifampicin on the pharmacokinetics and pharmacodynamics of aliskiren. The hypothesis

13  
14 was that rifampicin may reduce the plasma concentrations and the renin-inhibiting

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
effect of aliskiren.

For Peer Review

## METHODS

### Subjects

Twelve healthy white Finnish volunteers (7 women, 5 men) participated in the study after giving written informed consent. Their mean  $\pm$  SD age was  $21 \pm 2$  years (range, 20-25 years), mean height  $174 \pm 10$  cm (range, 156-187 cm), and mean weight  $66 \pm 11$  kg (range, 50-89 kg). Participants were ascertained to be healthy by medical history, physical examination, and routine laboratory tests. Subjects with a systolic blood pressure less than 110 mm Hg were not included in the study. None of the participants was on any continuous medication, including oral contraceptives, and none was a tobacco smoker.

### Study design

The study protocol was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District, and the National Agency for Medicines in Finland. In a randomized two-phase crossover study with a wash-out period of four weeks, the volunteers took 600 mg rifampicin (Rimapen; Orion Pharma, Espoo, Finland) or placebo once daily at 20<sub>00</sub> h for five days. On day six, after an overnight fast, a single oral dose of 150 mg aliskiren (Rasilez; Novartis, Horsham, Great Britain) was administered with 150 ml of water at 08<sub>00</sub> h. A standardized warm meal was served 4 h after the administration of aliskiren, and a standardized light meal after 7 h and 10 h. The participants were under direct medical supervision for 12 h after aliskiren ingestion. Fluids for intravenous infusion were available for immediate use in case of hypotension, but were not needed. Use of other drugs was prohibited for one week before and after,

1  
2  
3 and use of grapefruit products and alcohol for five days before and three days after  
4  
5 aliskiren administration.  
6  
7

### 8 9 **Blood sampling and pharmacodynamic measurements**

10  
11 On the days of the administration of aliskiren, a forearm vein of each subject was  
12  
13 cannulated with a plastic cannula and kept patent with an obturator. Timed blood  
14  
15 samples for drug concentration measurements (5 or 10 ml each) were drawn into tubes  
16  
17 containing ethylenediaminetetraacetic acid (EDTA) prior to and 0.5, 1, 2, 3, 4, 5, 7, 9,  
18  
19 12, 24, 34, 48, and 72 h after aliskiren administration. Blood samples for the  
20  
21 determination of plasma renin activity (5 ml each) were drawn before the administration  
22  
23 of aliskiren and 4 h and 24 h thereafter into chilled EDTA tubes, which were placed on  
24  
25 ice immediately after sampling. Plasma was separated within 30 min. Urine was  
26  
27 collected up to 12 h after aliskiren ingestion. Urine aliquots and plasma were stored at -  
28  
29 70°C until analysis. Plasma renin activity was measured using a commercially available  
30  
31 radioimmunoassay method (RENCTK; DiaSorin, Saluggia, Italy). Systolic and diastolic  
32  
33 blood pressures, and heart rate were measured twice (mean value was used in the  
34  
35 calculations) from the forearm with an automatic oscillometric blood pressure monitor  
36  
37 (Omron M5-I; Omron Healthcare Europe BV, Hoofddorp, The Netherlands), with the  
38  
39 subject in a sitting position, prior to and 2, 4, 7, 9, 12, and 24 h after the administration  
40  
41 of aliskiren.  
42  
43

### 44 45 **Determination of aliskiren concentrations**

46  
47 Plasma and urine concentrations of aliskiren were quantified using an Applied  
48  
49 Biosystems SCIEX API 2000 Q Trap liquid chromatography-tandem mass spectrometry  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



(LC/MS/MS) system (Sciex Division of MDS Inc, Toronto, Ontario, Canada) [5].

Acebutolol served as an internal standard. The limit of quantification of plasma

aliskiren was 0.25 ng/ml, and the intra-day coefficient of variation (CV) was 1.2% at 2

ng/ml, 1.0% at 20 ng/ml, and 1.2% at 200 ng/ml ( $n=6$ ). The calibration curve for plasma

aliskiren was linear over the range 0.25-500 ng/ml ( $r>0.999$ , weighting 1/x). The limit

of quantification of aliskiren in urine was 9 ng/ml, and the intra-day CV was 4.8% at 9

ng/ml, 4.5% at 120 ng/ml, and 3.4% at 1200 ng/ml ( $n=6$ ). The calibration curve for

urine aliskiren was linear over the range 9-1800 ng/ml ( $r>0.999$ , weighting 1/x).

Deleted: between

Deleted:

Deleted:

Deleted: 2

Deleted: between

Deleted: 2

Deleted:

Deleted:

### Pharmacokinetics

The pharmacokinetics of aliskiren were characterized by  $C_{max}$ , time to  $C_{max}$  ( $t_{max}$ ),  $t_{1/2}$ ,

$AUC_{0-72}$ ,  $AUC_{0-\infty}$ , the amount of aliskiren excreted into urine from 0 to 12 h ( $A_e$ ), and

the renal clearance ( $Cl_{renal}$ ). Pharmacokinetic parameters were calculated with non-

compartmental methods using MK-Model, version 5.0 (Biosoft, Cambridge, United

Kingdom). The terminal log-linear part of each concentration-time curve was identified

visually. The elimination rate constant ( $k_e$ ) was determined by linear regression analysis

of the log-linear part of the plasma drug concentration-time curve. The  $t_{1/2}$  was calculated

by the equation  $t_{1/2} = \ln 2/k_e$ . The AUC values were calculated by a combination of the

linear and log-linear trapezoidal rules with extrapolation to infinity, when appropriate,

by division of the last measured concentration by  $k_e$ . The  $Cl_{renal}$  of aliskiren was

calculated by the equation  $Cl_{renal} = A_e/AUC_{0-12}$ .

### Pharmacodynamics

1  
2  
3 The pharmacodynamics of aliskiren were characterized by plasma renin activity at 4 h  
4 and 24 h after aliskiren intake, as well as average systolic and diastolic blood pressures,  
5 and heart rate. Average values of systolic and diastolic blood pressures and heart rate  
6 were calculated by dividing the area under the effect-time curve from 0 to 24 h by 24 h.  
7  
8  
9  
10

### 11 12 13 **Statistical analysis**

14  
15 The results are expressed as geometric means (95% confidence interval), unless  
16 otherwise indicated. The  $C_{\max}$ , AUC, Ae, and  $Cl_{\text{renal}}$  data were logarithmically  
17 transformed before statistical analysis. Statistical comparisons of the pharmacokinetic  
18 (other than  $t_{\max}$ ) and pharmacodynamic variables during the placebo and rifampicin  
19 phases were carried out using repeated-measures analysis of variance with treatment  
20 phase as a within-subjects factor and treatment sequence as a between-subjects factor.  
21 The  $t_{\max}$  data were compared using the Wilcoxon signed rank test. The frequencies of  
22 individuals with a double-peak in aliskiren plasma concentration curve were compared  
23 between the phases using the McNemar test. Possible correlations between the  
24 pharmacokinetic variables of aliskiren and subject body weight were analyzed with the  
25 Pearson correlation coefficient. The data were analyzed using the statistical program  
26 SPSS 16.0 for Windows (SPSS, Chicago, IL, USA). Differences were considered  
27 statistically significant when  $P$  was  $<0.05$ . The number of subjects was estimated to be  
28 sufficient to detect a 40% difference in the  $AUC_{0-\infty}$  of aliskiren between the placebo and  
29 rifampicin phases, with a power of 80% ( $\alpha$ -level 5%) [4].  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: mean values  $\pm$  SD in the text and tables and, for clarity, as mean values  $\pm$  SEM in the figures

Deleted:

Deleted: November

Deleted: 09

## RESULTS

### Effect of rifampicin on aliskiren pharmacokinetics

Rifampicin markedly reduced the plasma concentrations of aliskiren (Fig. 1, Table 1).

The  $C_{\max}$  of aliskiren was reduced by 39% ( $P=0.017$ ) and its  $AUC_{0-\infty}$  by 56% ( $P<0.001$ )

by rifampicin. The  $A_e$  was decreased by 48% by rifampicin ( $P=0.001$ ). Rifampicin had

no significant effect on the  $t_{\max}$ ,  $t_{1/2\alpha}$  or  $Cl_{\text{renal}}$  of aliskiren. The extent of the interaction

showed marked interindividual variability: decrease in aliskiren  $AUC_{0-\infty}$  ranged from

20% to 76% and the effect of rifampicin on the aliskiren  $C_{\max}$  ranged from a 78%

decrease to a 9% increase (Fig. 2). Plasma aliskiren concentration showed a double-

peak in 11 out of 12 subjects during the placebo phase and 6 out of 12 subjects during

the rifampicin phase ( $P=0.063$ ). None of the pharmacokinetic variables of aliskiren

correlated with subject body weight, during either the placebo or rifampicin phase

( $|r|<0.38$ ,  $P>0.23$ ).

Deleted: mean

Deleted: 47

Deleted:

Deleted:

Deleted: mean

Deleted: 60

Deleted:

Deleted:

Deleted: 51

Deleted:

Deleted:

Deleted:

Deleted:

### Effect of rifampicin on aliskiren pharmacodynamics

Plasma renin activity 24 h after aliskiren intake was 61% higher during the rifampicin

phase than during the placebo phase ( $P=0.008$ ) (Fig. 3, Table 2). No significant

difference existed in the systolic or diastolic blood pressure, or the heart rate between

the rifampicin and placebo phases.

Deleted:

Deleted:

## DISCUSSION

This study demonstrates that rifampicin markedly reduces the plasma concentrations of aliskiren. The  $C_{\max}$  and  $AUC_{0-\infty}$  of aliskiren were reduced by 39% and 56%, respectively. Marked interindividual variability was evident in the extent of the interaction. Plasma renin activity 24 h after aliskiren intake was 61% higher during the rifampicin phase than during the placebo phase. The interaction between rifampicin and aliskiren may result in a need to adjust aliskiren dose.

Deleted: mean

Deleted: 47

Deleted: 60

Deleted: is probably clinically important and

Aliskiren, a drug with a low oral bioavailability, is a substrate of P-glycoprotein efflux transporter and is slightly metabolized by CYP3A4 [3, 5, 6]. In the present study, rifampicin reduced the  $C_{\max}$  and  $AUC_{0-\infty}$  of aliskiren without affecting the  $t_{1/2}$  or the  $Cl_{\text{renal}}$ , indicating that rifampicin increased mainly the first-pass elimination of aliskiren with no or minimal effect on its systemic clearance. Rifampicin has a strong inducing effect on intestinal and hepatic CYP3A4 with a smaller, though significant, effect on P-glycoprotein [16-22]. It is noteworthy that intestinal CYP3A4 and P-glycoprotein act synergistically to reduce the oral bioavailability of their joint substrates [23].

Deleted: the

Deleted: the

Because aliskiren has a low hepatic extraction ratio (0.10) [24], induction of its hepatic elimination unlikely explains this interaction observed during the first-pass phase. Moreover, significant change in the hepatic extraction of such a drug with a low hepatic extraction should result in a shortened elimination  $t_{1/2}$ . In addition, plasma aliskiren concentration data showed double-peaks characteristic of entero-hepatic circulation, particularly during the placebo phase. This phenomenon appeared to be diminished

Deleted: November

Deleted: 09

1  
2  
3 during the rifampicin phase, consistent with reduced intestinal reabsorption of aliskiren  
4  
5 due to induction of intestinal P-glycoprotein and CYP3A4. Taken together, the  
6  
7 interaction between rifampicin and aliskiren is most likely caused by induction of P-  
8  
9 glycoprotein-mediated efflux and CYP3A4-catalyzed biotransformation of aliskiren in  
10  
11 the gut wall [16-22].  
12

Deleted: the

13  
14  
15 In this study, the renin-inhibiting effect of aliskiren was attenuated during the rifampicin  
16  
17 phase. However, no differences in hemodynamic effects were observed between the  
18  
19 rifampicin and placebo phases after a single dose of aliskiren in healthy volunteers. This  
20  
21 can be explained by the delayed start of the blood pressure decreasing effect of  
22  
23 aliskiren, which gradually reaches its maximum after four weeks treatment [15, 25].  
24  
25 Moreover, the pharmacodynamic response to aliskiren in patients with hypertension  
26  
27 may be distinct from normotensive healthy individuals [3, 15]. On the other hand, the  
28  
29 pharmacokinetics of aliskiren is similar in patients with hypertension and healthy  
30  
31 individuals [3, 15]. According to pharmacokinetic theory, the dose-interval AUC at  
32  
33 steady state is equal to the  $AUC_{0-\infty}$  after a single dose [26]. However, the  
34  
35 pharmacokinetics of aliskiren is slightly non-linear [3], interfering with the direct  
36  
37 extrapolation of the present results to steady-state. Because aliskiren shows a dose-  
38  
39 response relationship in the range 150-300 mg, but no clear effect on blood pressure  
40  
41 with lower doses [15, 25], it is possible that rifampicin reduces the efficacy of aliskiren  
42  
43 in patients with hypertension. Similarly to rifampicin, a high-fat meal has reduced the  
44  
45 AUC of aliskiren by about 70% [3]. To minimize variability due to the food effect,  
46  
47 aliskiren is recommended to be taken once daily with a light meal or in a routine pattern  
48  
49 with regard to meals [15, 27].  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: ¶

In addition to rifampicin, also other inducers of CYP3A4 and the P-glycoprotein may interact with aliskiren. The antiepileptic drugs carbamazepine and phenytoin are approximately similarly potent inducers of CYP3A4 as rifampicin [19, 20, 25], whereas St John's wort has a smaller, though significant, effect [26]. Carbamazepine and phenytoin have reduced the AUC of the orally given CYP3A4 probe substrate midazolam (not a substrate of the P-glycoprotein [27]) by 94% and rifampicin by 96-98% [19, 20, 25, 28]. Phenytoin has reduced the AUC of oral digoxin (a substrate of the P-glycoprotein but not of CYP3A4 [21, 29, 30]) by 23% and rifampicin by 30% [21, 31], but carbamazepine treatment has not affected the oral bioavailability of digoxin [32]. St John's wort extract has reduced the AUC of oral midazolam by 52% and the AUC of oral digoxin by 25% [26, 33].¶

Deleted: Aliskiren is approved for the treatment of hypertension at once daily oral doses of 150 mg and 300 mg, and its antihypertensive effect is attained in two weeks [15]. Blood pressure reduction with 75-mg aliskiren has not been consistently greater than with placebo [15, 34, 35]. Therefore, during continuous treatment it is probable that rifampicin reduces the antihypertensive effect of aliskiren.

Deleted: 36

Deleted: November

Deleted: 09

In conclusion, rifampicin considerably reduces the plasma concentrations of aliskiren.

Clinicians should be aware of the possibility that rifampicin may reduce the

antihypertensive efficacy of aliskiren.

Deleted: by inducing its P-glycoprotein-mediated transport and CYP3A4-catalyzed biotransformation. The efficacy of aliskiren is likely to be reduced by rifampicin and other inducers of the P-glycoprotein and CYP3A4.¶

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### ACKNOWLEDGEMENTS

We thank Kaisa Kurkinen for the drug concentration measurements, and Mikko Neuvonen, Eija Mäkinen-Pulli, Lisbet Partanen and Jouko Laitila for skilled assistance. This study was supported by grants from the Helsinki University Central Hospital Research Fund (Helsinki, Finland) and the Sigrid Jusélius Foundation (Helsinki, Finland).

### COMPETING INTEREST

None to declare.

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1 Wood JM, Maibaum J, Rahuel J, Grütter MG, Cohen NC, Rasetti V, Rüter H, Gösche R, Stutz S, Fuhrer W, Schilling W, Rigollier P, Yamaguchi Y, Cumin F, Baum HP, Schnell CR, Herold P, Mah R, Jensen C, O'Brien E, Stanton A, Bedigian MP (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. *Biochem Biophys Res Commun* 308 (4): 698-705
- 2 Skeggs LT, Jr., Kahn JR, Lentz K, Shumway NP (1957) The preparation, purification, and amino acid sequence of a polypeptide renin substrate. *J Exp Med* 106 (3): 439-453
- 3 Vaidyanathan S, Jarugula V, Dieterich HA, Howard D, Dole WP (2008) Clinical pharmacokinetics and pharmacodynamics of aliskiren. *Clin Pharmacokinet* 47 (8): 515-531
- 4 Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R (2006) Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. *Br J Clin Pharmacol* 62 (6): 690-698
- 5 Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, Vaidyanathan S (2007) Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. *Drug Metab Dispos* 35 (8): 1418-1428



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 6 Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP (2008) Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. *J Clin Pharmacol* 48 (11): 1323-1338
- 7 Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. *Trends Pharmacol Sci* 25 (8): 423-429
- 8 Jurima-Romet M, Crawford K, Cyr T, Inaba T (1994) Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals. *Drug Metab Dispos* 22 (6): 849-857
- 9 Olkkola KT, Backman JT, Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. *Clin Pharmacol Ther* 55 (5): 481-485
- 10 Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW (2002) Interaction of common azole antifungals with P glycoprotein. *Antimicrob Agents Chemother* 46 (1): 160-165
- 11 Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. *Clin Pharmacol Ther* 75 (1): 13-33

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 12 Rao US, Scarborough GA (1994) Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. *Mol Pharmacol* 45 (4): 773-776
- 13 Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT (2005) Cyclosporine markedly raises the plasma concentrations of repaglinide. *Clin Pharmacol Ther* 78 (4): 388-399
- 14 Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. *Gastroenterology* 130 (6): 1793-1806
- 15 European Public Assessment Report for Rasilez. Available from URL:<http://www.emea.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm>. Accessed Nov 17, 2009.
- 16 Combalbert J, Fabre I, Fabre G, Dalet I, Derancourt J, Cano JP, Maurel P (1989) Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450III A gene subfamily. *Drug Metab Dispos* 17 (2): 197-207
- 17 Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of rifampin-inducible P450III A4 (CYP3A4) in human small bowel enterocytes. *J Clin Invest* 90 (5): 1871-1878

1  
2  
3 18 Schuetz EG, Beck WT, Schuetz JD (1996) Modulators and substrates of  
4  
5 P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in  
6  
7 human colon carcinoma cells. *Mol Pharmacol* 49 (2): 311-318  
8  
9

10  
11 19 Backman JT, Olkkola KT, Neuvonen PJ (1996) Rifampin drastically  
12  
13 reduces plasma concentrations and effects of oral midazolam. *Clin Pharmacol Ther* 59  
14  
15 (1): 7-13  
16  
17

18  
19 20 Backman JT, Kivistö KT, Olkkola KT, Neuvonen PJ (1998) The area  
20  
21 under the plasma concentration-time curve for oral midazolam is 400-fold larger during  
22  
23 treatment with itraconazole than with rifampicin. *Eur J Clin Pharmacol* 54 (1): 53-58  
24  
25

26  
27 21 Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O,  
28  
29 Zundler J, Kroemer HK (1999) The role of intestinal P-glycoprotein in the interaction of  
30  
31 digoxin and rifampin. *J Clin Invest* 104 (2): 147-153  
32  
33

34  
35 22 Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT (2003)  
36  
37 Pharmacokinetic interactions with rifampicin : clinical relevance. *Clin Pharmacokinet*  
38  
39 42 (9): 819-850  
40  
41

42  
43 23 Kivistö KT, Niemi M, Fromm MF (2004) Functional interaction of  
44  
45 intestinal CYP3A4 and P-glycoprotein. *Fundam Clin Pharmacol* 18 (6): 621-626  
46  
47

48  
49 24 Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition  
50  
51 with aliskiren: where are we now, and where are we going? *J Hypertens* 24 (2): 243-256  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: November

Deleted: 09

25 [Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL \(2007\) Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 49 \(11\): 1157-63](#)

26 [Rowland M, Tozer TN \(1995\) Clinical pharmacokinetics: Concepts and applications, 3rd edn. Williams & Wilkins, Baltimore](#)

27 [Tekturna Prescribing Information. Available from URL: <http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf>. Accessed Nov 17, 2009.](#)

Deleted: 25 . Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ (1996) Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. *Epilepsia* 37 (3): 253-257 ¶

26 . Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD (2001) The effects of St John's wort (*Hypericum perforatum*) on human cytochrome P450 activity. *Clin Pharmacol Ther* 70 (4): 317-326 ¶

27 . Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR (1999) Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. *Pharm Res* 16 (3): 408-414 ¶

28 . Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989) Oxidation of midazolam and triazolam by human liver cytochrome P450III4. *Mol Pharmacol* 36 (1): 89-96 ¶

29 . Lacarelle B, Rahmani R, de Sousa G, Durand A, Placidi M, Cano JP (1991) Metabolism of digoxin, digoxigenin digoxosides and digoxigenin in human hepatocytes and liver microsomes. *Fundam Clin Pharmacol* 5 (7): 567-582 ¶

30 . Hinderling PH, Hartmann D (1991) Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. *Ther Drug Monit* 13 (5): 381-401 ¶

31 . Rameis H (1985) On the interaction between phenytoin and digoxin. *Eur J Clin Pharmacol* 29 (1): 49-53 Johne A, Brockmüller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 66 (4): 338-345 ¶

32 . Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandström R (2008) Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. *Clin Pharmacol Ther* 84 (1): 52-62 ¶

33 . Johne A, Brockmüller J, Baue ... [1]

Deleted: 34 . Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A (2007) Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens* 20 (1): 11-20 ¶

35 . Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J (2007) Renin inhibition with aliskiren provides ... [2]

Deleted: 36

Deleted: .

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: November

Deleted: 09

Deleted: Table 1 Pharmacokinetic variables of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily

Variable ... [3]

Formatted Table

Formatted: Right

Formatted: Right

Formatted: Right

Formatted: Right

Formatted: Right

Formatted: Right

Formatted: Right

Formatted: Right

Formatted: Right

**Table 1** Pharmacokinetic variables of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily

<u>Variable</u>	<u>Placebo phase</u> <u>(control)</u>	<u>Rifampicin phase</u>	<u>Geometric mean ratio/</u> <u>mean difference</u> <u>(95% CI)</u>	<u>P value</u>
<u>C<sub>max</sub> (ng/ml)</u>	<u>137 (83, 226)</u>	<u>83 (59, 118)</u>	<u>0.61 (0.41, 0.90)</u>	<u>0.017</u>
<u>t<sub>max</sub> (h)</u>	<u>1 (0.5-5)</u>	<u>0.5 (0.5-5)</u>		<u>0.254</u>
<u>t<sub>1/2</sub> (h)</u>	<u>28.4 ± 8.5</u>	<u>24.4 ± 7.4</u>	<u>-4.0 (-9.6, 1.6)*</u>	<u>0.143</u>
<u>AUC<sub>0-72</sub> (ng·h/ml)</u>	<u>537 (349, 825)</u>	<u>244 (182, 325)</u>	<u>0.45 (0.36, 0.57)</u>	<u>&lt;0.001</u>
<u>AUC<sub>0-∞</sub> (ng·h/ml)</u>	<u>581 (376, 898)</u>	<u>258 (191, 349)</u>	<u>0.44 (0.35, 0.56)</u>	<u>&lt;0.001</u>
<u>Ae (mg)</u>	<u>0.576 (0.403, 0.822)</u>	<u>0.299 (0.227, 0.394)</u>	<u>0.52 (0.38, 0.72)</u>	<u>0.001</u>
<u>Cl<sub>renal</sub> (l/h)</u>	<u>1.52 (1.21, 1.91)</u>	<u>1.63 (1.38, 1.93)</u>	<u>1.07 (0.91, 1.26)</u>	<u>0.347</u>

Data are given as geometric mean (95% CI), t<sub>max</sub> data as median (range), and t<sub>1/2</sub> data as mean ± SD.

CI, Confidence interval; C<sub>max</sub>, peak plasma concentration; t<sub>max</sub>, time to C<sub>max</sub>; t<sub>1/2</sub>, elimination half-life; AUC<sub>0-72</sub>, area under the plasma concentration-time curve from 0 to 72 h; AUC<sub>0-∞</sub>, area under the plasma concentration-time curve from time 0 to infinity; Ae, amount excreted into urine within 12 h; Cl<sub>renal</sub>, renal clearance.

\*Mean difference (95% CI).

**Table 2** Pharmacodynamic variables of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily

Variable	Placebo phase (control)	Rifampicin phase	Mean difference (95% CI)	P value
Plasma renin activity (ng/ml/h)				
Baseline	2.21 ± 1.95	2.20 ± 1.40	-0.01 (-1.04, 1.01)	0.980
At 4 h	0.01 ± 0.04	0.19 ± 0.39	0.18 (-0.09, 0.45)	0.166
At 24 h	1.27 ± 1.20	2.04 ± 1.11	0.77 (0.25, 1.29)	0.008
Systolic blood pressure (mm Hg)				
Baseline	124 ± 15	127 ± 15	4 (-1, 8)	0.078
Average <sub>0-24h</sub>	126 ± 13	126 ± 16	0 (-4, 4)	0.847
Average <sub>0-24h</sub> /Baseline	1.02 ± 0.06	0.99 ± 0.03	-0.03 (-0.07, 0.01)	0.093
Diastolic blood pressure (mm Hg)				
Baseline	77 ± 11	76 ± 9	0 (-5, 5)	0.926
Average <sub>0-24h</sub>	74 ± 10	73 ± 8	-1 (-6, 3)	0.482
Average <sub>0-24h</sub> /Baseline	0.97 ± 0.06	0.95 ± 0.06	-0.02 (-0.07, 0.04)	0.544
Heart rate (1/min)				
Baseline	63 ± 13	64 ± 7	1 (-5, 7)	0.729
Average <sub>0-24h</sub>	70 ± 12	69 ± 9	0 (-5, 5)	0.888
Average <sub>0-24h</sub> /Baseline	1.11 ± 0.09	1.08 ± 0.07	-0.03 (-0.08, 0.02)	0.233

Data are given as mean ± SD.

CI, Confidence interval; Baseline, before the administration of aliskiren.

Deleted: November

Deleted: 09

## FIGURE LEGENDS

**Fig. 1** Geometric mean (95% confidence interval) plasma concentrations of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily. Inset depicts the same data on a semi-logarithmic scale

Deleted: Mean ± SEM

**Fig. 2** Box-and-whisker plots of the  $C_{max}$ , AUC and  $t_{1/2}$  values of aliskiren. A single 150 mg oral dose of aliskiren was given to twelve healthy volunteers following a 5-day treatment with 600 mg rifampicin or placebo once daily. The horizontal lines inside the boxes represent the median, the box edges show the lower and upper quartiles, and the whiskers show the 5th and 95th percentiles. Individual data points are given as open (placebo phase) and solid (rifampicin phase) circles

Deleted: Individual

Deleted: in twelve healthy volunteers after a

**Fig. 3** Box-and-whisker plots of plasma renin activity in twelve healthy volunteers 0, 4, and 24 after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily. The horizontal lines inside the boxes represent the median, the box edges show the lower and upper quartiles, and the whiskers show the 5th and 95th percentiles. Individual data points are given as open (placebo phase) and solid (rifampicin phase) circles

Deleted: Mean ± SEM plasma renin activity in twelve healthy volunteers after

Formatted: English (U.K.)

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Page 18: [1] Deleted** **tapatui20** **1/25/2010 3:16:00 PM**
- 25 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ (1996)  
Concentrations and effects of oral midazolam are greatly reduced in patients treated with  
carbamazepine or phenytoin. *Epilepsia* 37 (3): 253-257
- 26 Wang Z, Gorski JC, Hamman MA, Huang SM, Lesko LJ, Hall SD (2001)  
The effects of St John's wort (*Hypericum perforatum*) on human cytochrome P450  
activity. *Clin Pharmacol Ther* 70 (4): 317-326
- 27 Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ,  
Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR (1999)  
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.  
*Pharm Res* 16 (3): 408-414
- 28 Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA (1989)  
Oxidation of midazolam and triazolam by human liver cytochrome P450III<sub>A4</sub>. *Mol*  
*Pharmacol* 36 (1): 89-96
- 29 Lacarelle B, Rahmani R, de Sousa G, Durand A, Placidi M, Cano JP (1991)  
Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes  
and liver microsomes. *Fundam Clin Pharmacol* 5 (7): 567-582
- 30 Hinderling PH, Hartmann D (1991) Pharmacokinetics of digoxin and main  
metabolites/derivatives in healthy humans. *Ther Drug Monit* 13 (5): 381-401



- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 31 Rameis H (1985) On the interaction between phenytoin and digoxin. *Eur J Clin Pharmacol* 29 (1): 49-53
- Johne A, Brockmüller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 66 (4): 338-345
- 32 Magnusson MO, Dahl ML, Cederberg J, Karlsson MO, Sandström R (2008) Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin. *Clin Pharmacol Ther* 84 (1): 52-62
- 33 Johne A, Brockmüller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999) Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (*Hypericum perforatum*). *Clin Pharmacol Ther* 66 (4): 338-345
- 
- Page 18: [2] Deleted** **tapatui20** **1/25/2010 3:24:00 PM**
- 34 Pool JL, Schmieder RE, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A (2007) Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. *Am J Hypertens* 20 (1): 11-20
- 35 Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, Zhang J (2007) Renin inhibition with aliskiren provides additive

antihypertensive efficacy when used in combination with hydrochlorothiazide. J

Hypertens 25 (1): 217-226

Page 19: [3] Deleted

tapatui20

1/25/2010 2:49:00 PM

**Table 1** Pharmacokinetic variables of aliskiren in twelve healthy volunteers after a single 150 mg oral dose of aliskiren following a 5-day treatment with 600 mg rifampicin or placebo once daily

Variable	Placebo phase (control)	Rifampicin phase	% of control (range)	Geometric mean difference (95% CI)
$C_{\max}$ (ng/ml)	179 ± 134	95 ± 55	53% (22-109%)	0.61 (0.41, 0.81)
$t_{\max}$ (h)	1 (0.5-5)	0.5 (0.5-5)		
$t_{1/2}$ (h)	28.4 ± 8.5	24.4 ± 7.4	86% (52-131%)	-4.0 (-9.6, 1.6)
$AUC_{0-72}$ (ng·h/ml)	661 ± 457	270 ± 138	41% (24-81%)	0.45 (0.36, 0.54)
$AUC_{0-\infty}$ (ng·h/ml)	718 ± 501	288 ± 150	40% (24-80%)	0.44 (0.35, 0.53)
Ae (mg)	0.662 ± 0.365	0.326 ± 0.144	49% (27-104%)	0.52 (0.38, 0.66)
$Cl_{\text{renal}}$ (l/h)	1.60 ± 0.44	1.69 ± 0.45	106% (74-184%)	1.07 (0.91, 1.23)

Data are given as mean ± SD,  $t_{\max}$  data as median (range).

CI, Confidence interval;  $C_{\max}$ , peak plasma concentration;  $t_{\max}$ , time to  $C_{\max}$ ;  $t_{1/2}$ , elimination half-life;  $AUC_{0-72}$ , area under the plasma concentration-time curve from 0 to 72 h;  $AUC_{0-\infty}$ , area under the plasma concentration-time curve from time 0 to infinity; Ae, amount excreted into urine within 12 h;  $Cl_{\text{renal}}$ , renal clearance.

\*Mean difference (95% CI).